Description

• Itraconazole Super Bioavailability

1. Broad-spectrum antifungal therapy with FDA approval for superficial fungal infections.
2. Ensures increased bioavailability compared to conventional Itraconazole for dermatophytosis.
3. More patients reported remarkable improvement, complete clearance of symptoms, and clearance of lesions than with conventional Itraconazole.
4. Achieves higher sebum concentration compared to conventional Itraconazole.
5. Significantly improves pruritus, scaling, and erythema.
6. Proven superior to Terbinafine, with higher clinical and mycological cure rates in the treatment of tinea corporis and tinea cruris.
7. Offers a favorable tolerability profile with improved patient adherence.

• Indicated in:

1. Superficial Fungal Infections
2. Cutaneous Mycoses